Group items tagged

LYSAKER, Norway, April 11, 2008-An increased intake of vitamin K2 may reduce the risk of prostate cancer by 35 per cent, suggest results from the European Prospective Investigation into Cancer and Nutrition (EPIC). The findings, based on dietary intake from 11,319 men taking part in the EPIC Heidelberg cohort, are published in this month's issue of the American Journal of Clinical Nutrition.

Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H. J Hepatol. 2009 Aug;51(2):315-21. Epub 2009 May 15. PMID: 19501932 CONCLUSIONS: The combination treatment of VK and ACE-I may suppress the cumulative recurrence of HCC after the curative therapy, at least partly through suppression of the VEGF-mediated neovascularization.

Dietary intake of vitamin K and risk of prostate cancer in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg).\nNimptsch K, Rohrmann S, Linseisen J.\nAm J Clin Nutr. 2008 Apr;87(4):985-92.\nPMID: 18400723